Vanguard Group’s Amylyx Pharmaceuticals AMLX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $28.8M | Buy |
4,498,028
+381,516
| +9% | +$2.45M | ﹤0.01% | 2383 |
|
|
2025
Q1 | $14.6M | Buy |
4,116,512
+1,424,023
| +53% | +$5.04M | ﹤0.01% | 2646 |
|
|
2024
Q4 | $10.2M | Sell |
2,692,489
-397,156
| -13% | -$1.5M | ﹤0.01% | 2946 |
|
|
2024
Q3 | $10M | Sell |
3,089,645
-1,134,323
| -27% | -$3.68M | ﹤0.01% | 2961 |
|
|
2024
Q2 | $8.03M | Sell |
4,223,968
-1,124,171
| -21% | -$2.14M | ﹤0.01% | 3035 |
|
|
2024
Q1 | $15.2M | Buy |
5,348,139
+72,573
| +1% | +$206K | ﹤0.01% | 2728 |
|
|
2023
Q4 | $77.7M | Buy |
5,275,566
+225,486
| +4% | +$3.32M | ﹤0.01% | 1986 |
|
|
2023
Q3 | $92.5M | Buy |
5,050,080
+124,188
| +3% | +$2.27M | ﹤0.01% | 1848 |
|
|
2023
Q2 | $106M | Buy |
4,925,892
+178,551
| +4% | +$3.85M | ﹤0.01% | 1822 |
|
|
2023
Q1 | $139M | Buy |
4,747,341
+388,849
| +9% | +$11.4M | ﹤0.01% | 1644 |
|
|
2022
Q4 | $161M | Buy |
4,358,492
+844,136
| +24% | +$31.2M | ﹤0.01% | 1552 |
|
|
2022
Q3 | $98.9M | Buy |
3,514,356
+2,520,355
| +254% | +$70.9M | ﹤0.01% | 1790 |
|
|
2022
Q2 | $19.1M | Buy |
994,001
+1,813
| +0.2% | +$34.9K | ﹤0.01% | 2656 |
|
|
2022
Q1 | $12.8M | Buy |
+992,188
| New | +$12.8M | ﹤0.01% | 3024 |
|